狂犬病病毒CTN-1V株在人二倍体细胞Walvax-2株的适应传代  

Adaption and passage rabies virus strain CTN-1V in a human diploid cell strain Walvax-2

作　　者：何丽芳 陈敏 张益丽 任正勇 胡超 高显专 赵振鑫 马万 李兵 白梅 马波 

机构地区：[1]云南沃森生物技术股份有限公司,云南昆明650106

出　　处：《微生物学免疫学进展》2014年第5期1-4,共4页Progress In Microbiology and Immunology

基　　金：国家科技重大专项(2013ZX10004003);云南省科技计划项目任务-基础研究计划重大项目(2013FC005)

摘　　要：目的：建立狂犬病病毒固定毒CTN-1V株在人二倍体细胞Walvax-2株上的传代适应株。方法用狂犬病病毒固定毒CTN-1V株经昆明小鼠鼠脑回传后的病毒接种Walvax-2细胞，连续传代，检测各代次病毒的滴度及免疫原性。结果CTN-1V株能较好地适应Walvax-2细胞，通过连续带毒传代至第7代，病毒滴度可达6．78lgLD50/mL，并在第10～15代内滴度维持在7．0lgLD50/mL以上，15～30代滴度稳定在7．0lgLD50/mL左右。以15代适应毒株CTN-1V-HDCP15制备的疫苗原液，各项指标均符合《中华人民共和国药典》三部（2010版）的要求，疫苗效力在6．0IU/剂以上。结论所获人胚肺二倍体细胞Walvax-2株传代适应狂犬病毒固定毒株CTN-1V-HDC可用于人用狂犬病疫苗的生产开发。Objective To develop a rabies virus fixed virus adaption strain on human embryo lung diploid cell strain Walvax -2.Methods The rabies fixed virus strain ,CTN-1V,was inoculated in Kunming mice brains ,followed by being continuously passaged in Walvax-2 cells,titers for all passages and immunogenicity for every 5 passages were detected .Resutl s CTN-1V strain can adapte to human diploid Walvax-2 cell.By continuously passaging in Walvax-2 strain,the virus titer reached 6.88 lg LD50/mL at 9th passage,maintained above 7.0 lg LD50/mL from 10th to 15th passages,and stabilized around 7.0 lg LD50/mL from 15th to 30th passages.All indicators of the vaccine bulk prepared from virus adaption strain CTN-1V-HDC P15 met the requirements of “Chinese Pharmacopeia” volume III（ 2010 edition）, all of vaccine efficacy were above 6.0 IU/dose. Conclusion The developed rabies virus strain CTN-1V-HDC, adapted and passaged on human embryo lung diploid cell strain Walvax-2 ,can be used in development and production of human rabies vaccine .

关 键 词：狂犬病毒CTN-1V株 人胚肺二倍体细胞 适应 传代 狂犬病疫苗 

分 类 号：R373.9[医药卫生—病原生物学]